Interactions of High Salt Intake and the Response of the Cardiovascular System to Aldosterone
- 1 May 2005
- journal article
- research article
- Published by Wolters Kluwer Health in Cardiology in Review
- Vol. 13 (3) , 118-124
Abstract
High salt intake contributes to the risk of hypertension, and this effect is in part mediated by the physiologic action of aldosterone on renal mineralocorticoid receptors. However, the actions of aldosterone are not restricted to the kidneys, because aldosterone can bind to mineralocorticoid receptors in the heart, vasculature, and brain to produce structural and functional changes that lead to target organ damage. Experimental and clinical studies show that, in the setting of high salt intake, blocking aldosterone at the mineralocorticoid receptor reduces progression to target organ damage and preserves vascular function. In many cases, these benefits are independent of changes in blood pressure. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have short-term effects on reducing aldosterone levels, but frequently aldosterone levels return to pretreatment levels during long-term therapy. Aldosterone blockade may be more completely achieved with mineralocorticoid receptor antagonists. Spironolactone has been shown to have substantial and significant benefits in experimental and clinical studies of cardiac dysfunction. Eplerenone is a selective aldosterone blocker with a greater binding affinity for mineralocorticoid receptors than for androgen and progesterone receptors. Eplerenone has similarly demonstrated significant benefits in experimental animals and in patients with left ventricular dysfunction after myocardial infarction. Thus, aldosterone blockade with mineralocorticoid receptor antagonists offers target organ protection and may blunt some of the adverse effects of chronic high salt intake.Keywords
This publication has 52 references indexed in Scilit:
- Elevated Plasma Aldosterone Levels Despite Complete Inhibition of the Vascular Angiotensin-Converting Enzyme in Chronic Heart FailureCirculation, 2002
- Pathophysiological effects of aldosterone in cardiovascular tissuesTrends in Endocrinology & Metabolism, 2001
- Aldosterone as a Determinant of Cardiovascular and Renal DysfunctionJournal of the Royal Society of Medicine, 2001
- Aldosterone Production Is Activated in Failing Ventricle in HumansCirculation, 2001
- Expression of 11beta-hydroxylase and aldosterone synthase genes in the rat brainJournal of Molecular Endocrinology, 2000
- Comparison of Candesartan, Enalapril, and Their Combination in Congestive Heart FailureCirculation, 1999
- Blood Pressure and End-Stage Renal Disease in MenNew England Journal of Medicine, 1996
- Aldosterone: intracellular receptors in human heartEuropean Heart Journal, 1995
- Aldosterone escape during ACE inhibitor therapy in chronic heart failureEuropean Heart Journal, 1995
- Blood pressure (systolic and diastolic) and risk of fatal coronary heart disease.Hypertension, 1989